Home > Cardiology > ACC/WCC 2020 > Vascular Medicine and Thromboembolism > Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?

Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?

Presented By
Dr G.R. Hong, Yonsei University College of Medicine, South Korea
Conference
ACC 2020
Trial
ENAVLE
After surgical or mitral valve replacements or repair, 3 months of edoxaban was non-inferior to warfarin for preventing thromboembolism and major bleeding. Dr Geu-Ru Hong (Yonsei University College of Medicine, South Korea) presented the results of the open-label, parallel group, randomised Korean ENAVLE study, which aimed to explore the efficacy of edoxaban in patients after mitral valve repair or bioprosthetic valve implantation [1]. Dr Hong pointed out that 3 months of warfarin administration after surgical or transcatheter valve therapy is common practice in Korea. The problem is that a Korean diet typically includes high levels of vitamin K that can interfere with the efficacy of warfarin. Thus, the investigators in this trial sought to identify an alternative among the direct oral anticoagulants (DOACs). The primary efficacy endpoint was the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on